Feasibility of conducting a primary prevention trial of low-dose aspirin for major adverse cardiovascular events in older people in Australia: Results from the ASPirin in Reducing Events in the Elderly (ASPREE) pilot study

Abstract

Aim: To determine the feasibility of performing a large clinical trial of the use of aspirin for the primary prevention of cardiovascular disease in older participants - the ASPirin in Reducing Events in the Elderly (ASPREE) trial. Design and participants: A randomised double-blind placebo-controlled pilot trial of 100 mg of enteric-coated aspirin tablets daily, in men and women aged 70 years and over who did not have overt cardiovascular disease, and who were followed for 12 months. Participants were identified from the computer databases of general practitioners who were co-investigators in a previous trial. Setting: The Melbourne metropolitan area between March 2003 and June 2005. Main ou..